Literature DB >> 34665432

Bioinformatics Prediction and Analysis of MicroRNAs and Their Targets as Biomarkers for Prostate Cancer: A Preliminary Study.

Chipampe Patricia Lombe1,2, Mervin Meyer3, Ashley Pretorius3,4.   

Abstract

Prostate cancer (PCa) is the second most common form of cancer in men around the world. Due to its heterogeneity, presentations range from aggressive lethal disease to indolent disease. There is a need to identify core biomarkers that are important for early detection and progression, allowing a more precise method for the treatment and management of Pca. We obtained metastatic prostate cancer associated microRNA array profiles from the GSE28029 dataset in the GEO database. MicroRNA target prediction was done using the databases, TargetScanHuman, miRDB and DIANA microT, six target genes (FOXC1, CDKN1A, BIRC2, CTNND1, ELK1 and LRP8) were found to be common among the three different databases. Differential expression of the target genes was performed via the GENT2 database in the GPL96 platform (HG-U133A). Results indicated all genes were downregulated. Gene Ontology (GO) was used to perform enrichment analysis. The GO enrichment analysis indicated that the downregulated genes were enriched in cellular response to gamma radiation, regulation of transcription and response to drugs as well as protein binding and receptor signaling protein activity. The study suggested that CDKN1A, FOXC1 and BIRC2 might be core genes for prostate cancer that play an important role in its diagnosis, development and progression.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  In silico; MicroRNA; Prostate cancer; qPCR

Mesh:

Substances:

Year:  2021        PMID: 34665432     DOI: 10.1007/s12033-021-00414-8

Source DB:  PubMed          Journal:  Mol Biotechnol        ISSN: 1073-6085            Impact factor:   2.695


  37 in total

Review 1.  Clinical practice. Prostate-specific-antigen testing for early diagnosis of prostate cancer.

Authors:  M J Barry
Journal:  N Engl J Med       Date:  2001-05-03       Impact factor: 91.245

Review 2.  Aberrant regulation and function of microRNAs in cancer.

Authors:  Brian D Adams; Andrea L Kasinski; Frank J Slack
Journal:  Curr Biol       Date:  2014-08-18       Impact factor: 10.834

3.  Serum miR-1181 and miR-4314 associated with ovarian cancer: MiRNA microarray data analysis for a pilot study.

Authors:  Lihong Ruan; Yuanyuan Xie; Fangmei Liu; Xuehua Chen
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  2018-01-09       Impact factor: 2.435

4.  Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends.

Authors:  Ruth Etzioni; David F Penson; Julie M Legler; Dante di Tommaso; Rob Boer; Peter H Gann; Eric J Feuer
Journal:  J Natl Cancer Inst       Date:  2002-07-03       Impact factor: 13.506

Review 5.  Systemic therapy in men with metastatic castration-resistant prostate cancer:American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline.

Authors:  Ethan Basch; D Andrew Loblaw; Thomas K Oliver; Michael Carducci; Ronald C Chen; James N Frame; Kristina Garrels; Sebastien Hotte; Michael W Kattan; Derek Raghavan; Fred Saad; Mary-Ellen Taplin; Cindy Walker-Dilks; James Williams; Eric Winquist; Charles L Bennett; Ted Wootton; R Bryan Rumble; Stacie B Dusetzina; Katherine S Virgo
Journal:  J Clin Oncol       Date:  2014-09-08       Impact factor: 44.544

6.  miR-203a suppresses cell proliferation by targeting E2F transcription factor 3 in human gastric cancer.

Authors:  Huiqin Yang; Lixia Wang; Xiaoli Tang; Wenmei Bai
Journal:  Oncol Lett       Date:  2017-10-17       Impact factor: 2.967

7.  Specificity of serum prostate-specific antigen determination in the Finnish prostate cancer screening trial.

Authors:  L Määttänen; M Hakama; T L J Tammela; M Ruutu; M Ala-Opas; H Juusela; P Martikainen; U-H Stenman; A Auvinen
Journal:  Br J Cancer       Date:  2007-01-15       Impact factor: 7.640

8.  MicroRNA-8073: Tumor suppressor and potential therapeutic treatment.

Authors:  Atsuko Mizoguchi; Aiko Takayama; Taiga Arai; Junpei Kawauchi; Hiroko Sudo
Journal:  PLoS One       Date:  2018-12-27       Impact factor: 3.240

Review 9.  Liquid Biopsy in Oligometastatic Prostate Cancer-A Biologist's Point of View.

Authors:  Ewelina Stelcer; Marek Konkol; Aleksandra Głȩboka; Wiktoria Maria Suchorska
Journal:  Front Oncol       Date:  2019-08-14       Impact factor: 6.244

Review 10.  Epigenetic alteration and microRNA dysregulation in cancer.

Authors:  Hiromu Suzuki; Reo Maruyama; Eiichiro Yamamoto; Masahiro Kai
Journal:  Front Genet       Date:  2013-12-03       Impact factor: 4.599

View more
  1 in total

1.  Regulation of Let-7a-5p and miR-199a-5p Expression by Akt1 Modulates Prostate Cancer Epithelial-to-Mesenchymal Transition via the Transforming Growth Factor-β Pathway.

Authors:  Abdulrahman Alwhaibi; Varun Parvathagiri; Arti Verma; Sandeep Artham; Mir S Adil; Payaningal R Somanath
Journal:  Cancers (Basel)       Date:  2022-03-23       Impact factor: 6.639

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.